{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T17:16:56Z","timestamp":1779124616743,"version":"3.51.4"},"reference-count":90,"publisher":"Cambridge University Press (CUP)","license":[{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["Acta Neuropsychiatr."],"published-print":{"date-parts":[[2025]]},"abstract":"<jats:title>Abstract<\/jats:title>\n\t  <jats:sec id=\"S0924270824000589_as1\">\n\t    <jats:title>Objective:<\/jats:title>\n\t    <jats:p>Combining different pharmaceuticals may be beneficial when treating disorders with complex neurobiology, including alcohol use disorder (AUD). The gut-brain peptides amylin and GLP-1 may be of potential interest as they individually reduce alcohol intake in rodents. While the combination of amylin receptor (AMYR) and glucagon-like peptide-1 receptor (GLP-1R) agonists have been found to decrease feeding and body weight in obese male rats synergistically, their combined impact on alcohol intake is unknown.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S0924270824000589_as2\">\n\t    <jats:title>Methods:<\/jats:title>\n\t    <jats:p>Therefore, the effect of the combination of an AMYR (salmon calcitonin (sCT)) and a GLP-1R (dulaglutide) agonist on alcohol intake in rats of both sexes was explored in two separate alcohol-drinking experiments. The first alcohol-drinking experiment evaluated the potential of adding sCT to an ongoing dulaglutide treatment, whereas the second alcohol-drinking experiment examined the effect when adding sCT and dulaglutide simultaneously.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S0924270824000589_as3\">\n\t    <jats:title>Results:<\/jats:title>\n\t    <jats:p>When adding sCT to an ongoing dulaglutide treatment, a reduction in alcohol intake was observed in both male and female rats. However, when combining sCT and dulaglutide simultaneously, an initial reduction in alcohol intake was observed in rats of both sexes, whereas tolerance towards treatment was observed. In both alcohol-drinking experiments, this treatment combination consistently decreased food consumption and body weight in males and females. While the treatment combination did not affect inflammatory mediators, the gene expression of AMYR or GLP-1R, it changed fat tissue morphology.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S0924270824000589_as4\">\n\t    <jats:title>Conclusions:<\/jats:title>\n\t    <jats:p>Further investigation needs to be done on the combination of AMYR and GLP-1R agonists to assess their combined effects on alcohol intake.<\/jats:p>\n\t  <\/jats:sec>","DOI":"10.1017\/neu.2024.58","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T06:13:34Z","timestamp":1733465614000},"update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":2,"title":["The combination of a glucagon-like peptide-1 and amylin receptor agonists reduces alcohol consumption in both male and female rats"],"prefix":"10.1017","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5325-1667","authenticated-orcid":false,"given":"Cajsa","family":"Aran\u00e4s","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian E.","family":"Edvardsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay","family":"Zentveld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Vall\u00f6f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Witley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian","family":"Tufvesson-Alm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olesya T.","family":"Shevchouk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesper","family":"Vestlund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2408-3165","authenticated-orcid":false,"given":"Elisabet","family":"Jerlhag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"key":"S0924270824000589_ref52","first-page":"219","article-title":"Alcohol\u2019s effects on the cardiovascular system","volume":"38","author":"Piano","year":"2017","journal-title":"Alcohol Research"},{"key":"S0924270824000589_ref24","doi-asserted-by":"crossref","first-page":"e12910","DOI":"10.1111\/adb.12910","article-title":"Effects of a selective long-acting amylin receptor agonist on alcohol consumption, food intake and body weight in male and female rats","volume":"26","author":"Kalafateli","year":"2021","journal-title":"Addiction biology"},{"key":"S0924270824000589_ref28","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-444-62619-6.00003-3"},{"key":"S0924270824000589_ref38","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-9781(99)00208-9"},{"key":"S0924270824000589_ref57","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00418.2016"},{"key":"S0924270824000589_ref71","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1111\/acer.13199","article-title":"Effects of the GLP-1 agonist exendin-4 on intravenous ethanol self-administration in mice","volume":"40","author":"S\u00f8rensen","year":"2016","journal-title":"Alcoholism: Clinical and Experimental Research"},{"key":"S0924270824000589_ref16","doi-asserted-by":"crossref","first-page":"e91936","DOI":"10.1371\/journal.pone.0091936","article-title":"The burden attributable to mental and substance use disorders as risk factors for suicide: findings from the global burden of disease study 2010","volume":"9","author":"Ferrari","year":"2014","journal-title":"PLoS One"},{"key":"S0924270824000589_ref17","doi-asserted-by":"publisher","DOI":"10.1080\/13813455.2017.1308382"},{"key":"S0924270824000589_ref59","doi-asserted-by":"publisher","DOI":"10.1111\/j.1369-1600.2011.00327.x"},{"key":"S0924270824000589_ref23","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12603"},{"key":"S0924270824000589_ref77","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-020-00923-1"},{"key":"S0924270824000589_ref61","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41598-020-80894-x","article-title":"Dulaglutide exerts beneficial anti atherosclerotic effects in apoE knockout mice with diabetes: the earlier, the better","volume":"11","author":"Sanada","year":"2021","journal-title":"Scientific reports"},{"key":"S0924270824000589_ref44","doi-asserted-by":"publisher","DOI":"10.1177\/1535370217732041"},{"key":"S0924270824000589_ref14","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/B978-0-444-63425-2.00009-X","article-title":"Alcohol: mechanisms along the mesolimbic dopamine system","volume":"211","author":"Engel","year":"2014","journal-title":"Progress in Brain Research"},{"key":"S0924270824000589_ref26","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.159863","article-title":"Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial","volume":"7","author":"Klausen","year":"2022","journal-title":"JCI Insight"},{"key":"S0924270824000589_ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2011.12.022"},{"key":"S0924270824000589_ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2020.101967"},{"key":"S0924270824000589_ref88","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.170419"},{"key":"S0924270824000589_ref13","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2002.018671"},{"key":"S0924270824000589_ref63","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.45.26746"},{"key":"S0924270824000589_ref85","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2017.06.013"},{"key":"S0924270824000589_ref11","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0140-6736(19)31775-1","article-title":"Alcohol use disorders","volume":"394","author":"Carvalho","year":"2019","journal-title":"Lancet"},{"key":"S0924270824000589_ref37","doi-asserted-by":"publisher","DOI":"10.1016\/0031-9384(95)02067-5"},{"key":"S0924270824000589_ref66","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1111\/j.1530-0277.2008.00753.x","article-title":"Intermittent access to 20% ethanol induces high ethanol consumption in long-evans and wistar rats","volume":"32","author":"Simms","year":"2008","journal-title":"Alcoholism, clinical and experimental research"},{"key":"S0924270824000589_ref79","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.02.020"},{"key":"S0924270824000589_ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.nutres.2018.12.007"},{"key":"S0924270824000589_ref84","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.05.016"},{"key":"S0924270824000589_ref42","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2013.66"},{"key":"S0924270824000589_ref72","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1326-9-30"},{"key":"S0924270824000589_ref65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061965"},{"key":"S0924270824000589_ref73","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2018.03.001"},{"key":"S0924270824000589_ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2022.101444"},{"key":"S0924270824000589_ref55","first-page":"844","article-title":"The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in apoE(-\/-) and LDLr(-\/-) mice by a mechanism that includes inflammatory pathways","volume":"3","author":"Rakipovski","year":"2018","journal-title":"JACC: Basic to Translational Science"},{"key":"S0924270824000589_ref5","doi-asserted-by":"crossref","DOI":"10.1152\/ajpregu.00275.2010","article-title":"Dose combinations of exendin-4 and salmon calcitonin produce additive and synergistic reductions in food intake in nonhuman primates","volume":"299","author":"Bello","year":"2010","journal-title":"American journal of physiology. Regulatory, integrative and comparative physiology"},{"key":"S0924270824000589_ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2014.04.006"},{"key":"S0924270824000589_ref51","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/0091-3057(80)90196-3","article-title":"Calcitonin reduces feeding in man, monkey and rat","volume":"12","author":"Perlow","year":"1980","journal-title":"Pharmacology, biochemistry, and behavior"},{"key":"S0924270824000589_ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-6273(00)81056-9"},{"key":"S0924270824000589_ref30","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-020-00678-2"},{"key":"S0924270824000589_ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2006.02.001"},{"key":"S0924270824000589_ref62","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1211958"},{"key":"S0924270824000589_ref21","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00498"},{"key":"S0924270824000589_ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118258"},{"key":"S0924270824000589_ref70","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-28720-6_170"},{"key":"S0924270824000589_ref83","article-title":"Combined GLP-1 receptor agonist and amylin analogue pharmacotherapy to treat obesity comorbid with Type 1 Diabetes","volume":"1","author":"Wong","year":"2023","journal-title":"JCEM Case Report"},{"key":"S0924270824000589_ref41","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2012.140"},{"key":"S0924270824000589_ref78","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12295"},{"key":"S0924270824000589_ref50","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.585887"},{"key":"S0924270824000589_ref35","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0596"},{"key":"S0924270824000589_ref36","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.811401"},{"key":"S0924270824000589_ref69","doi-asserted-by":"crossref","first-page":"e12807","DOI":"10.1111\/adb.12807","article-title":"Combined administration of varenicline and bupropion produces additive effects on accumbal dopamine and abolishes the alcohol deprivation effect in rats","volume":"25","author":"S\u00f6derpalm","year":"2020","journal-title":"Addiction biology"},{"key":"S0924270824000589_ref3","doi-asserted-by":"publisher","DOI":"10.1515\/hmbci-2016-0051"},{"key":"S0924270824000589_ref80","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2009.04.010"},{"key":"S0924270824000589_ref12","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.psyneuen.2012.11.009","article-title":"The glucagon-like peptide 1 analogue exendin-4 attenuates alcohol mediated behaviors in rodents","volume":"38-38","author":"Egecioglu","year":"2013","journal-title":"Psychoneuroendocrinology"},{"key":"S0924270824000589_ref48","doi-asserted-by":"publisher","DOI":"10.1111\/acer.13577"},{"key":"S0924270824000589_ref43","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/bs.pbr.2017.07.006","article-title":"Paraventricular thalamus: gateway to feeding, appetitive motivation, and drug addiction","volume":"235","author":"Millan","year":"2017","journal-title":"Progress in Brain Research"},{"key":"S0924270824000589_ref74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0078154"},{"key":"S0924270824000589_ref56","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.20070993"},{"key":"S0924270824000589_ref76","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2019.02.006"},{"key":"S0924270824000589_ref82","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.107898"},{"key":"S0924270824000589_ref18","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/dmrr.1080","article-title":"Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein","volume":"26","author":"Glaesner","year":"2010","journal-title":"Diabetes\/Metabolism Research and Reviews"},{"key":"S0924270824000589_ref75","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.1092828"},{"key":"S0924270824000589_ref54","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-022-01129-w"},{"key":"S0924270824000589_ref67","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1001\/archgenpsychiatry.2011.49","article-title":"Effects of adrenal sensitivity, stress- and cue-induced craving, and anxiety on subsequent alcohol relapse and treatment outcomes","volume":"68","author":"Sinha","year":"2011","journal-title":"Archives of General Psychiatry"},{"key":"S0924270824000589_ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-015-0143-4"},{"key":"S0924270824000589_ref53","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-48267-2"},{"key":"S0924270824000589_ref64","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/nature07182","article-title":"PRDM16 controls a brown fat\/skeletal muscle switch","volume":"454","author":"Seale","year":"2008","journal-title":"Nature"},{"key":"S0924270824000589_ref81","doi-asserted-by":"crossref","first-page":"104687","DOI":"10.1016\/j.psyneuen.2020.104687","article-title":"Glucagon-like peptide-1 receptors and sexual behaviors in male mice","volume":"117","author":"Vestlund","year":"2020","journal-title":"Psychoneuroendocrinology"},{"key":"S0924270824000589_ref87","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.694476"},{"key":"S0924270824000589_ref27","first-page":"144","article-title":"The potential of neuroscience to inform treatment.(FOCUS ON: NEUROSCIENCE AND TREATMENT)","volume":"33","author":"Koob","year":"2010","journal-title":"Alcohol research and health"},{"key":"S0924270824000589_ref34","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2212\u0394\u0394CT method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods (San Diego, California)"},{"key":"S0924270824000589_ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108511"},{"key":"S0924270824000589_ref7","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/dom.12824","article-title":"Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials","volume":"19","author":"Bettge","year":"2017","journal-title":"Diabetes, obesity and metabolism"},{"key":"S0924270824000589_ref33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-44591-8"},{"key":"S0924270824000589_ref39","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.599646"},{"key":"S0924270824000589_ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2015.02.014"},{"key":"S0924270824000589_ref47","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.21-21-08324.2001"},{"key":"S0924270824000589_ref60","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2011.01537.x"},{"key":"S0924270824000589_ref19","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.cmet.2014.03.007","article-title":"Prdm16 is required for the maintenance of brown adipocyte identity and function in adult mice","volume":"19","author":"Harms","year":"2014","journal-title":"Cell Metabolism"},{"key":"S0924270824000589_ref2","doi-asserted-by":"crossref","first-page":"104642","DOI":"10.1016\/j.ebiom.2023.104642","article-title":"Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats","volume":"93","author":"Aran\u00e4s","year":"2023","journal-title":"EBioMedicine"},{"key":"S0924270824000589_ref90","first-page":"5","article-title":"Social media as pharmacovigilance: the potential for patient reports to inform clinical research on glucagon-like peptide 1 (GLP-1) receptor agonists for substance use disorders","volume":"85","author":"Bremmer","year":"2024","journal-title":"Journal of Studies on Alcohol and Drugs"},{"key":"S0924270824000589_ref29","doi-asserted-by":"publisher","DOI":"10.3109\/07853890.2011.611529"},{"key":"S0924270824000589_ref4","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.90327.2008"},{"key":"S0924270824000589_ref68","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.1969.49.2.330"},{"key":"S0924270824000589_ref89","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.13776"},{"key":"S0924270824000589_ref86","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2019.04.004"},{"key":"S0924270824000589_ref32","doi-asserted-by":"publisher","DOI":"10.1152\/advan.00052.2006"},{"key":"S0924270824000589_ref22","first-page":"1093","article-title":"An amylin analogue attenuates alcohol-related behaviours in various animal models of alcohol use disorder","volume":"44","author":"Kalafateli","year":"2019","journal-title":"Neuropsychopharmacology (New York, N.Y.)"},{"key":"S0924270824000589_ref58","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.23m15068"},{"key":"S0924270824000589_ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2012.04.001"},{"key":"S0924270824000589_ref10","doi-asserted-by":"publisher","DOI":"10.1089\/met.2018.0075"}],"container-title":["Acta Neuropsychiatrica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0924270824000589","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T12:07:38Z","timestamp":1742818058000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0924270824000589\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":90,"alternative-id":["S0924270824000589"],"URL":"https:\/\/doi.org\/10.1017\/neu.2024.58","relation":{},"ISSN":["0924-2708","1601-5215"],"issn-type":[{"value":"0924-2708","type":"print"},{"value":"1601-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,6]]},"assertion":[{"value":"\u00a9 The Author(s), 2024. Published by Cambridge University Press on behalf of Scandinavian College of Neuropsychopharmacology","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https:\/\/creativecommons.org\/licenses\/by\/4.0\/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"e42"}}